The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | 2025 updates in targeted therapies and immunotherapy for liver cancer
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, describes recent advances in precision medicine for liver cancer. Novel immunotherapy targets such as TIM3 and TIGIT are under development and cytokines targeting IL27 have shown promise. A recently presented trial has additionally demonstrated the efficacy of an FGFR4 inhibitor with atezolizumab. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The current standard treatment for liver cancer is the doublet IO or the IO plus VEGF, and of course, there are many, many studies and different thoughts on how to improve the treatment further. One is that we try to add some new targets. At this moment, I think the TIGIT is something that is being tested in the phase three setting and, of course, there’s some other immune checkpoint inhibitors like TIM3 that may also add to the immunotherapy...
The current standard treatment for liver cancer is the doublet IO or the IO plus VEGF, and of course, there are many, many studies and different thoughts on how to improve the treatment further. One is that we try to add some new targets. At this moment, I think the TIGIT is something that is being tested in the phase three setting and, of course, there’s some other immune checkpoint inhibitors like TIM3 that may also add to the immunotherapy. There are some studies showing that we may target the cytokines like interleukin-27; this may also be combined with the immunotherapy backbone and improve some of the response rate and survival. Apart from IO, I think another potentially important one is the FGFR4 inhibitors. There’s an abstract in the ESMO GI this year that, when you combine with atezolizumab, actually, you do see, and in those patients with FGFR4 amplified HCC, you do see respectable response rate. I think this may also point towards some of the precision medicine, that we need to biopsy the patient to test some of the biomarkers beforehand. So, I think these are the three areas that possibly are important in the future, where we develop some new treatment for the liver cancer patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Personal, Advisory Board: Eisai, AstraZeneca, MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Eisai, Roche, Ipsen, BMS; Financial Interests, Institutional, Research Grant: Eisai, MSD; Non-Financial Interests, Other, Head of External Relations: International Liver Cancer Association (ILCA)
